Data from a national AAT deficiency-targeted screening cohort showed that approximately a quarter of PI*MZ samples showed signs of inflammation, as evidenced by increased levels of C-reactive protein (CRP) ≥ 5 mg/L [21]. The gene discussed is CRP; the disease is alpha 1-antitrypsin deficiency.